Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

A. Michael Lincoff(Cleveland Clinic), John H. Alexander(Ohio State University Hospital), Richard C. Becker(University of Cincinnati), Thomas J. Povsic, Michael Aschermann, Mauricio G. Cohen(Santa Ana College), Viliam Fridrich(National Institute of Cardiovascular Diseases), Roxana Mehran(Mount Sinai Hospital), Mary Ann Sellers(Duke Medical Center), Jan H. Cornel(Brigham and Women's Hospital), Paul W. Armstrong(Canadian VIGOUR Centre), Christopher E. Buller(Teleflex (United States)), Warren J. Cantor(University of Toronto), Rod Stables(Liverpool Heart and Chest Hospital), Vic Hasselblad(American Urological Association), Marco Valgimigli(University of Bern), João Morais(Instituto Politécnico de Leiria), Peter Sinnaeve(Brigham and Women's Hospital), Peep Laanmets(North Estonia Medical Centre), Steven L. Zelenkofske(Novartis (Switzerland)), Victor Guetta(Sheba Medical Center), Renato D. Lópes(Duke University), Lauren Glenn(Regen BioPharma (United States)), Jarosław D. Kasprzak(Medical University of Lodz), Kurt Huber(Sigmund Freud Privatuniversität Wien), Béla Merkely(Semmelweis University), Toomas Marandi(North Estonia Medical Centre), José López‐Sendón(Hospital Universitario La Paz), Zhen Huang(Zhejiang Chinese Medical University), Christoph Bode(University Medical Center Freiburg), Marilyn Borgman(Cleveland Clinic), Arnold I. Levinson, Philippe Gabríel Steg(Mount Sinai Hospital)

The Lancet

November 5, 2015

Cited by 151

|New England Journal of Medicine|2011|9.4k

|New England Journal of Medicine|2017|9.1k

|New England Journal of Medicine|2009|7.1k

|European Heart Journal|2012|6.8k

|New England Journal of Medicine|2019|6.8k

Related Papers